Solifenacin for overactive bladder: Secondary analysis of data from VENUS based on baseline continence status

International Urogynecology Journal

Volumn 21, Issue 7, 2010, Pages 847-854

  Toglia, Marc R ^a   Ostergard, Donald R ^b   Appell, Rodney A ^c   Andoh, Masakazu ^d   Fakhoury, Allam ^e   Hussain, Iqbal F ^e  

^a Urogynecology Associates of Philadelphia   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d RHO INC   (United States)

^e ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

Continence status; Overactive bladder; Subjective assessment; Symptom bother; Urgency

Indexed keywords

PLACEBO; SOLIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; URINARY URGENCY; URINE INCONTINENCE; MALE; MIDDLE AGED; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 77952980385     PISSN: 09373462     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00192-010-1120-6     Document Type: Article

References (23)

1. P Abrams W Artibani L Cardozo R Dmochowski P van Kerrebroeck P Sand 2006 Reviewing the ICS 2002 terminology report: the ongoing debate Neurourol Urodyn 25 293 10.1002/nau.20251
2. P Abrams L Cardozo M Fall D Griffiths P Rosier U Ulmsten, et al. 2002 The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society Neurourol Urodyn 21 167 178 10.1002/nau.10052 11857671 (Pubitemid 34195211)
3. CR Chapple W Artibani LD Cardozo D Castro-Diaz M Craggs F Haab, et al. 2005 The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects BJU Int 95 335 340 10.1111/j.1464-410X.2005.05294.x 15679789 (Pubitemid 40283119)
4. DE Irwin I Milsom S Hunskaar K Reilly Z Kopp S Herschorn, et al. 2006 Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study Eur Urol 50 1306 1315 10.1016/j.eururo.2006.09.019 17049716 (Pubitemid 44692945)
5. I Milsom P Abrams L Cardozo RG Roberts J Thuroff AJ Wein 2001 How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 760 766 10.1046/j.1464-410x.2001. 02228.x 1:STN:280:DC%2BD3Mzls1OhtA%3D%3D 11412210 (Pubitemid 34204313)
6. WF Stewart JB Van Rooyen GW Cundiff P Abrams AR Herzog R Corey, et al. 2003 Prevalence and burden of overactive bladder in the United States World J Urol 20 327 336 1:STN:280:DC%2BD3s3osVWkuw%3D%3D 12811491 (Pubitemid 44175300)
7. CR Chapple V Khullar Z Gabriel D Muston CE Bitoun D Weinstein 2008 The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur Urol 54 543 562 10.1016/j.eururo.2008. 06.047 1:CAS:528:DC%2BD1cXhtFKisb%2FK 18599186
8. P Abrams S Swift 2005 Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis Eur Urol 48 483 487 1:CAS:528: DC%2BD2MXhtFSks7%2FO 16005564
9. VW Nitti R Dmochowski RA Appell JT Wang T Bavendam Z Guan 2006 Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia BJU Int 97 1262 1266 10.1111/j.1464-410X.2006. 06146.x 1:CAS:528:DC%2BD28XmsVaiurY%3D 16686723 (Pubitemid 43907334)
10. MC Michel JJ de la Rosette M Piro T Schneider 2005 Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder Eur Urol 48 110 115 10.1016/j.eururo.2004.11.012 15967259 (Pubitemid 40835603)
11. ES Rovner R Rackley VW Nitti JT Wang Z Guan 037 Study Group 2008 Tolterodine extended release is efficacious in continent and incontinent subjects with overactive bladder Urology 72 488 493 10.1016/j.urology.2008.05. 019 18639327
12. L Cardozo M Lisec R Millard TO van Vierssen I Kuzmin TE Drogendijk, et al. 2004 Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder J Urol 172 1919 1924 10.1097/01.ju.0000140729.07840.16 1:CAS:528: DC%2BD2cXps12jsrY%3D 15540755 (Pubitemid 39363090)
13. CR Chapple T Rechberger S Al-Shukri P Meffan K Everaert M Huang, et al. 2004 Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder BJU Int 93 303 310 10.1111/j.1464-410X.2004.04606.x 1:CAS:528:DC%2BD2cXis1ShsLo%3D 14764127 (Pubitemid 38253574)
14. M Gittelman FM Chu I Klimberg R Fincher N Smith D Tempel, et al. 2003 Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multi-center studies assess the efficacy and safety of daily oral administration of 10 mg YM905 versus placebo in male and female subjects with overactive bladder [abstract DP43] J Urol 169 349
15. MM Karram MR Toglia SR Serels M Andoh A Fakhoury S Forero-Schwanhaeuser 2009 Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial Urology 73 14 18 10.1016/j.urology.2008.08.485 18995887
16. MR Toglia SR Serels C Laramee MM Karram IM Nandy M Andoh, et al. 2009 Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial Postgrad Med 121 151 158 10.3810/pgm.2009.09.2062 19820284
17. L Cardozo A Dixon 2005 Increased warning time with darifenacin: a new concept in the management of urinary urgency J Urol 173 1214 1218 10.1097/01.ju.0000155798.78911.57 15758755 (Pubitemid 40380539)
18. A Nixon S Colman L Sabounjian B Sandage UE Schwiderski DR Staskin, et al. 2005 A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials J Urol 174 604 607 10.1097/01.ju.0000165461.38088.7b 16006914 (Pubitemid 40981612)
19. L Cardozo KS Coyne E Versi 2005 Validation of the urgency perception scale BJU Int 95 591 596 10.1111/j.1464-410X.2005.05345.x 15705086 (Pubitemid 40311479)
20. KS Coyne LS Matza Z Kopp P Abrams 2006 The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder Eur Urol 49 1079 1086 10.1016/j.eururo.2006.01. 007 16460875 (Pubitemid 43673993)
21. K Coyne D Revicki T Hunt R Corey W Stewart J Bentkover, et al. 2002 Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q Qual Life Res 11 563 574 10.1023/A:1016370925601 1:STN:280:DC%2BD38vkslWjug%3D%3D 12206577 (Pubitemid 34876130)
22. L Cardozo D Castro-Diaz M Gittelman A Ridder M Huang 2006 Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin Int Urogynecol J Pelvic Floor Dysfunct 17 512 519 10.1007/s00192-005-0058-6 16625311 (Pubitemid 44138259)
23. JH van Leeuwen R Castro M Busse BL Bemelmans 2006 The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms Eur Urol 50 440 452 10.1016/j.eururo.2006.05.014 16753253 discussion 453 (Pubitemid 44189071)